Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 1(3)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03875729Phase 3Completed

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Role: lead

NCT05788341Recruiting

The Israeli Study for Islet Autoantibodies Screening in Families of Type-1 Diabetes Patients

Role: collaborator

NCT03955666Phase 1Completed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects

Role: lead

NCT04690426Phase 1Completed

PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers

Role: lead

NCT03854305Phase 2Completed

Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease

Role: lead

NCT03849599Phase 1Completed

A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis

Role: lead

All 6 trials loaded